Doxorubicin-induced cardiomyopathy

Doxorubicin-induced cardiomyopathy is a toxic myocardial disorder affecting the cardiovascular system in pediatric and adult oncology patients treated with the anthracycline chemotherapeutic agent doxorubicin

Doxorubicin-induced cardiomyopathy is a toxic myocardial disorder affecting the cardiovascular system in pediatric and adult oncology patients treated with the anthracycline chemotherapeutic agent doxorubicin

Pathophysiologically, the condition is driven by cumulative, dose-dependent myocardial injury characterized by topoisomerase IIβ inhibition, mitochondrial dysfunction, reactive oxygen species generation, and disrupted calcium homeostasis, which culminate in cardiomyocyte death, myofibrillar loss, and myocardial fibrosis Clinically, it most frequently manifests as chronic or late-onset dilated cardiomyopathy marked by progressive left ventricular systolic dysfunction, reduced ejection fraction, c...

Pathophysiologically, the condition is driven by cumulative, dose-dependent myocardial injury characterized by topoisomerase IIβ inhibition, mitochondrial dysfunction, reactive oxygen species generation, and disrupted calcium homeostasis, which culminate in cardiomyocyte death, myofibrillar loss, and myocardial fibrosis Clinically, it most frequently manifests as chronic or late-onset dilated cardiomyopathy marked by progressive left ventricular systolic dysfunction, reduced ejection fraction, c...

Pathophysiologically, the condition is driven by cumulative, dose-dependent myocardial injury characterized by topoisomerase IIβ inhibition, mitochondrial dysfunction, reactive oxygen species generation, and disrupted calcium homeostasis, which culminate in cardiomyocyte death, myofibrillar loss, and myocardial fibrosis Clinically, it most frequently manifests as chronic or late-onset dilated cardiomyopathy marked by progressive left ventricular systolic dysfunction, reduced ejection fraction, c...